E-GEOD-50539 - Induction of sarcomas by mutant IDH2

Released on 21 October 2013, last updated on 25 November 2013
Homo sapiens
Samples (27)
Protocols (2)
More than 50% of patients with chondrosarcomas exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2. In this study, we performed genome-wide CpG methylation sequencing of chondrosarcoma biopsies and found that IDH mutations were associated with DNA hypermethylation at CpG islands but not other genomic regions. Regions of CpG island hypermethylation were enriched for genes implicated in stem cell maintenance/differentiation and lineage specification. In murine 10T1/2 mesenchymal 20 progenitor cells, expression of mutant IDH2 led to DNA hypermethylation and an impairment in differentiation that could be reversed by treatment with DNA-hypomethylating agents. Introduction of mutant IDH2 also induced loss of contact inhibition and generated undifferentiated sarcomas in vivo. The oncogenic potential of mutant IDH2 correlated with the ability to produce 2-hydroxyglutarate. Together, these data demonstrate that neomorphic IDH2 mutations can be oncogenic in mesenchymal cells.. RRBS sequencing of (1) IDH wild type and mutant human chondrosarcomas, (2) isogenic cell lines expressing wild-type or mutant IDH.
Experiment type
methylation profiling by high throughput sequencing 
Altuna Akalin, Andrew M Intlekofer, Ari Melnick, Chao Lu, Chong Chen, Christopher E Mason, Craig B Thompson, Fang Fang, Gary K Schwartz, Jiangbin Ye, John H Healey, Justin R Cross, Khedoudja Nafa, Meera Hameed, Narasimhan P Agaram, Patrick S Ward, Raya Khanin, Raymond G DeMatteo, Scott W Lowe, Sriram Venneti
Induction of sarcomas by mutant IDH2. Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB. , Europe PMC 24065766
Exp. designProtocolsVariablesProcessedSeq. reads